Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
04 Jun 2020 11:00 AM
RNS
Price Monitoring Extension
04 Jun 2020 09:05 AM
RNS
Second Price Monitoring Extn
04 Jun 2020 09:00 AM
RNS
Price Monitoring Extension
04 Jun 2020 07:01 AM
RNS
PrimaryBid.com Offers
04 Jun 2020 07:00 AM
RNS
Proposed Fundraising to raise up to £45 million
28 May 2020 07:00 AM
RNS
Posting of Annual Report and Notice of AGM
26 May 2020 11:05 AM
RNS
Second Price Monitoring Extn
26 May 2020 11:00 AM
RNS
Price Monitoring Extension
26 May 2020 08:06 AM
RNS
Issue of Equity
21 May 2020 02:05 PM
RNS
Second Price Monitoring Extn
21 May 2020 02:00 PM
RNS
Price Monitoring Extension
20 May 2020 07:00 AM
RNS
Distribution Agreement for COVID-19 Antigen Test
15 May 2020 04:41 PM
RNS
Second Price Monitoring Extn
15 May 2020 04:35 PM
RNS
Price Monitoring Extension
15 May 2020 02:06 PM
RNS
Second Price Monitoring Extn
15 May 2020 02:00 PM
RNS
Price Monitoring Extension
15 May 2020 11:06 AM
RNS
Second Price Monitoring Extn
15 May 2020 11:00 AM
RNS
Price Monitoring Extension
15 May 2020 09:30 AM
RNS
Issue of Equity
15 May 2020 07:00 AM
RNS
SARS-COV-2 Neutralising Affimers
11 May 2020 07:00 AM
RNS
Avacta Ships SARS-COV-2 Affimer Reagents
06 May 2020 07:00 AM
RNS
Results for the period ending 31 December 2019
05 May 2020 06:15 PM
RNS
Holding(s) in Company
04 May 2020 04:41 PM
RNS
Second Price Monitoring Extn
04 May 2020 04:36 PM
RNS
Price Monitoring Extension
01 May 2020 07:00 AM
RNS
COVID-19 Antigen Test Collaboration with Adeptrix
27 Apr 2020 05:30 PM
RNS
Holding(s) in Company
27 Apr 2020 05:00 PM
RNS
Holding(s) in Company
24 Apr 2020 06:00 PM
RNS
Holding(s) in Company
24 Apr 2020 04:41 PM
RNS
Second Price Monitoring Extn
24 Apr 2020 04:36 PM
RNS
Price Monitoring Extension
24 Apr 2020 02:05 PM
RNS
Second Price Monitoring Extn
24 Apr 2020 02:00 PM
RNS
Price Monitoring Extension
23 Apr 2020 04:40 PM
RNS
Second Price Monitoring Extn
23 Apr 2020 04:35 PM
RNS
Price Monitoring Extension
23 Apr 2020 10:18 AM
RNS
Result of General Meeting
22 Apr 2020 02:30 PM
RNS
Holding(s) in Company
22 Apr 2020 09:05 AM
RNS
Second Price Monitoring Extn
22 Apr 2020 09:00 AM
RNS
Price Monitoring Extension
22 Apr 2020 07:00 AM
RNS
Avacta/Cytiva Partnership Ahead of Schedule
20 Apr 2020 09:05 AM
RNS
Second Price Monitoring Extn
20 Apr 2020 09:00 AM
RNS
Price Monitoring Extension
17 Apr 2020 07:00 AM
RNS
Notice of Results - Update
16 Apr 2020 04:41 PM
RNS
Second Price Monitoring Extn
16 Apr 2020 04:36 PM
RNS
Price Monitoring Extension
16 Apr 2020 02:05 PM
RNS
Second Price Monitoring Extn
16 Apr 2020 02:00 PM
RNS
Price Monitoring Extension
15 Apr 2020 09:05 AM
RNS
Second Price Monitoring Extn
15 Apr 2020 09:00 AM
RNS
Price Monitoring Extension
14 Apr 2020 05:30 PM
RNS
Holding(s) in Company

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100